|
Acute Heart Failure Drug Trials Should Include Co-Primary Endpoints, EMA Says
Developers of acute heart failure drugs should conduct double-blind, randomized Phase III trials with co-primary endpoints, rather than composite endpoints, according to a European Medicines Agency (EMA) draft guideline.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives